Otsuka America Pharmaceutical, Inc.
37 articles with Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc., Earns Designation as a Great Place to Work-Certified™ Company In 2020
Otsuka America Pharmaceutical, Inc., (Otsuka) today announced that it is Great Place to Work-Certified™. Certification is a significant achievement. Using validated employee feedback gathered with Great Place to Work’s rigorous, data-driven “For All” methodology, Certification confirms at least seven out of 10 employees have a consistently positive experience at Otsuka. Great Place to Work is t
Otsuka Is Lead, Founding Sponsor of PBS’ WELL BEINGS Youth Mental Health Project, Featuring Ken Burns Documentary Series
New Multi-year Public Health Campaign and Documentary Focus on Mental Health Issues
Otsuka America Pharmaceutical, Inc. Provides Eligible, Newly Uninsured Patients in the U.S. With No-Cost Access to Its Medicines
Otsuka America Pharmaceutical, Inc. announces today the extension of its patient support program to provide “no-cost” access to its branded portfolio of prescription medicines for patients in the U.S. who have lost a job or health insurance coverage due to the COVID-19 (coronavirus) pandemic.
Otsuka America Pharmaceutical, Inc. Announces Sozosei Foundation Donations of $500,000 to Local Charities to Support Those Impacted by COVID-19 Pandemic
Five Local Charities Selected in New Jersey and Washington, D.C. Areas by Otsuka America Pharmaceutical, Inc., the Sozosei Foundation has committed $500,000 in donations to five local charities in central New Jersey and Washington, D.C. areas to support those impacted by the Covid-19 Pandemic. The charities selected focus on an array of critical services such as providing meals and h
Top Experts, Lawmakers and Advocates Come Together to Discuss Policy Solutions to Support Growing Number of Americans Living with Mental Illness
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
The ABILIFY MYCITE System, the first drug-device combination product to be approved by FDA to track drug ingestion, will be integrated into Magellan Health’s mental health provider network
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Gamida Cell today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
The Digital Therapeutics Alliance (DTA) welcomes nine companies to membership
Getting patients to adhere to long-term treatments can be difficult. There are a number of new therapies that will monitor whether or not patients are sticking to their regimen.
Avella announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD).
Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care
Held at Elevate by Psych Congress, a gathering of up-and-coming leaders in mental health care, the event featured some of the most groundbreaking technologies in the mental health marketplace.
Otsuka America Pharmaceutical, Inc. Release: Results Of New Survey Show Nearly Two Thirds Of Surveyed Adults With Major Depressive Disorder (MDD) Who Report Taking Their Medication As Prescribed Still Experience Symptoms At Least Weekly
Otsuka America Pharmaceutical, Inc. Release: FDA Approves Deltoid Injection Site For Abilify Maintena (Aripiprazole) For Extended-Release Injectable Suspension In The Treatment Of Schizophrenia
Otsuka America Pharmaceutical, Inc. And Lundbeck Inc. To Present Data On Investigational Compound Brexpiprazole In Schizophrenia And Major Depressive Disorder At American Psychiatric Association Annual Meeting
H. Lundbeck A/S and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: U.S. FDA Accepts For Review Supplemental New Drug Application For Deltoid Administration Of Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia